Is Compounded Tirzepatide for Sale Legal? What You Should Know
Is compounded tirzepatide legal in 2026? We explain 503A pharmacy rules, the FDA shortage resolution, court rulings and state-level regulations with primary sources.
The legality of compounded tirzepatide in 2026 is not a simple yes or no. The FDA resolved the tirzepatide shortage in December 2024, ending the broad exemption that allowed compounding pharmacies to produce it freely. Since then, 503A pharmacies may still compound tirzepatide, but only when a prescriber documents a specific clinical need that the FDA-approved product cannot meet. Court rulings, proposed FDA rules and state regulations continue to shape this landscape. This guide covers the primary sources.
The Short Answer on Legality
503A compounding pharmacies can still legally compound tirzepatide on a patient-specific prescription when there is a documented clinical need. General cost savings, patient preference or convenience do not meet the legal threshold for "clinical need." The regulatory environment is evolving, and providers should be able to explain their legal basis for compounding.
What Is a 503A Compounding Pharmacy?
Understanding the regulatory categories is essential to understanding the legality question. The two types of compounding operations in the US operate under different sections of federal law.
Section 503A of the FD&C Act
Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. These are state-licensed pharmacies that prepare medications based on individual patient prescriptions. The medication is compounded after a prescriber writes a patient-specific order. 503A pharmacies are primarily regulated by their state board of pharmacy, not the FDA.
Patient-Specific Prescriptions
The critical legal distinction: 503A compounding requires a valid prescription for a specific patient from a licensed prescriber. Mass production for general distribution is not permitted under 503A. Each compounded medication is prepared for one identified patient based on one prescriber's clinical judgment.
How 503A Differs from 503B Outsourcing Facilities
503B outsourcing facilities (governed by Section 503B) can compound medications in larger batches without patient-specific prescriptions. They are registered with the FDA and subject to FDA inspection. After the tirzepatide shortage ended, the wind-down deadline for 503B facilities was March 19, 2025. The Fifth Circuit affirmed in August 2026 that 503B bulk compounding of tirzepatide is no longer lawful.
The FDA Tirzepatide Shortage Timeline
The shortage status is the foundation of the compounding legal question. During a drug shortage, compounding pharmacies have broader authority to produce copies of the shortage drug. When the shortage ends, that authority narrows.
- December 2022: shortage declared Tirzepatide was added to the FDA drug shortage list due to supply constraints from Eli Lilly. This triggered the shortage exemption allowing compounding under both 503A and 503B.
- December 19, 2024: shortage resolved The FDA issued a declaratory order resolving the tirzepatide shortage, revoking and replacing an earlier October 2024 decision that had been remanded by a court.
- February 18, 2025: 503A wind-down 60-day wind-down deadline for state-licensed 503A pharmacies to transition away from shortage-based compounding.
- March 19, 2025: 503B wind-down 90-day deadline for 503B outsourcing facilities.
December 2022: Shortage Declared
When the tirzepatide shortage was added to the FDA list, both 503A and 503B pharmacies gained authority to compound tirzepatide. This broad exemption drove explosive growth in compounded tirzepatide providers during 2023 and 2024.
December 2024: Shortage Resolved
The FDA determined that Eli Lilly had restored adequate supply. The declaratory order resolved the shortage and set wind-down deadlines for compounders. This was the single most significant regulatory event for the compounded tirzepatide market.
Wind-Down Deadlines for Compounders
The 60-day (503A) and 90-day (503B) deadlines gave compounders time to fulfill existing orders and transition. After these dates, compounding tirzepatide requires meeting the standard (non-shortage) legal requirements, which are more restrictive.
Current Legal Status After the Shortage Ended
With the shortage resolved, the legal basis for compounding tirzepatide narrowed. What remains legal depends on the type of pharmacy and the clinical justification.
When 503A Compounding Is Still Permitted
After the wind-down, 503A pharmacies may compound tirzepatide if a licensed prescriber documents that the patient has a clinical need that the FDA-approved formulation (Zepbound or Mounjaro) cannot meet. This could include a verified allergy to an inactive ingredient in the commercial product.
The Clinical Need Requirement
The standard is specific: the prescriber must document why the FDA-approved product is inadequate for this particular patient. The legal analysis from Frier Levitt explains that the clinical need must be genuine and documented, not a workaround for price or convenience.
What Does Not Qualify as Clinical Need
Cost savings alone do not qualify. Patient preference does not qualify. Convenience does not qualify. If the only reason a patient chooses compounded tirzepatide over Zepbound is price, that does not meet the legal threshold under 503A after the shortage ended. This is a significant point that many online sellers do not address transparently.
Court Decisions on Compounded Tirzepatide
Multiple court cases have shaped the legal landscape in 2025 and 2026. Three are most significant.
Outsourcing Facilities Association v. FDA (Fifth Circuit)
The Outsourcing Facilities Association (OFA) challenged the FDA's decision to remove tirzepatide from the shortage list. In March 2025, a district court denied the preliminary injunction. The Fifth Circuit Court of Appeals affirmed the FDA's delisting in August 2026, ruling that 503B bulk compounding of tirzepatide for general use is no longer lawful.
Strive Specialties Antitrust Case
In August 2026, a federal judge dismissed an antitrust lawsuit brought by Strive Specialties (a compounding pharmacy) against Eli Lilly and Novo Nordisk. The court found that compounded GLP-1 medications and FDA-approved brand-name GLP-1s are not interchangeable products for antitrust purposes.
Eli Lilly v. Mochi Health
Eli Lilly sued Mochi Health, a telehealth company selling compounded tirzepatide, for unfair competition and false advertising. A California federal judge allowed most claims to proceed in April 2026. The case remains in discovery as of October 2026. If Lilly prevails, the likely outcome would be an injunction against Mochi's compounded tirzepatide sales.
| Case | Date | Outcome | Impact |
|---|---|---|---|
| OFA v. FDA (Fifth Circuit) | August 2026 | FDA affirmed | 503B compounding effectively ended |
| Strive v. Lilly/Novo (antitrust) | August 2026 | Dismissed | No antitrust relief for compounders |
| Lilly v. Mochi Health | Ongoing | Proceeding to discovery | Could set precedent for telehealth compounding |
State-Level Regulations
No US state has outright banned compounded tirzepatide. However, several states have tightened oversight of compounding pharmacies, particularly for sterile injectable products.
Stricter Oversight States
California requires compounding pharmacies to register with the state board, maintain detailed compounding logs and report adverse events within 24 hours. New York requires all compounded sterile preparations to be prepared in facilities meeting USP 797 standards. Massachusetts requires patient-specific prescriptions for all compounded medications and prohibits "office use" compounding.
Telehealth Prescribing Variations
State telehealth laws affect whether an out-of-state provider can prescribe to patients in that state. Some states require the prescriber to be licensed in the patient's state; others have reciprocity or compact agreements. This is why Arc-1 cannot serve five states: the combination of telehealth prescribing rules and pharmacy shipping regulations in those jurisdictions prevents their business model from operating there.
What This Means for Buyers
If you are considering compounded tirzepatide, understand that the legal basis has narrowed since the shortage ended. Legitimate providers should be able to explain how they comply with current regulations.
How to Confirm Your Provider Complies
Ask your provider these questions: What is the clinical need basis for compounding? Is the prescribing provider licensed in your state? Is the compounding pharmacy a licensed 503A facility? Both providers on this site (BiltRx and Arc-1) use 503A pharmacies and require a prescription. For detailed verification steps, see our safety guide.
FAQ - Compounded Tirzepatide Legality
Can I still buy compounded tirzepatide in 2026?
Yes, through 503A pharmacies when a prescriber documents a specific clinical need. The broad shortage exemption has ended, but patient-specific compounding under 503A remains legal under the right conditions. Verify with your provider that they meet current requirements.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or manufacturing quality. Only Zepbound and Mounjaro, manufactured by Eli Lilly, carry FDA approval.
What is the FDA proposed rule on the 503B Bulks List?
On April 30, 2026, the FDA proposed permanently excluding tirzepatide, semaglutide and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. The comment period closed in mid-2026. No final rule has been issued as of October 2026.
Can a doctor still prescribe compounded tirzepatide?
Yes, if the doctor documents a clinical need that the FDA-approved product cannot meet. The prescription goes to a 503A compounding pharmacy that prepares it for that specific patient. The clinical need must be genuine, not based solely on cost or convenience.
What happens if my state restricts compounded tirzepatide?
No state has banned compounded tirzepatide outright. Some states have stricter pharmacy regulations that affect which out-of-state pharmacies can ship into the state and how telehealth prescribing works. If your state is not served by your preferred provider, check whether the other provider covers your state or consider a brand-name prescription through a local physician and retail pharmacy.
Compare the current picks
Prices, sizes and ratings side by side, updated when the merchant pages change.
Get Tirzepatide